11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
View Patent ↗Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: are selective inhibitors of the 11β-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidernia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.
1. A compound represented by Formula I:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A and B may be taken separately or together;
when taken separately,
A represents halo, C 1-6 alkyl, OC 1-6 alkyl or phenyl, said alkyl, phenyl and the alkyl portion of OC 1-6 alkyl being optionally substituted with 1–3 halo groups; and
B represents represents H, halo, C 1-6 alkyl, —OC 1-6 alkyl, —SC 1-6 alkyl, C 2-6 alkenyl, phenyl or naphthyl, said alkyl, alkenyl, phenyl, naphthyl, and the alkyl portions of —OC 1-6 alkyl and —SC 1-6 alkyl being optionally substituted with 1–3 groups selected from halo, OH, CH 3 O, CF 3 and OCF 3 ; and
when taken together,
A and B together represents (a) C 1-4 alkylene optionally substituted with 1–3 halo groups, and 1–2 R a groups wherein R a represents C 1-3 alkyl, OC 1-3 alkyl, C 6-10 arC 1-6 alkylene or phenyl optionally substituted with 1–3 halo groups, or (b) C 2-5 alkanediyl such that they form a 3–6 membered ring with the carbon atom to which they are attached, said ring optionally containing 1 double bond or 1–2 heteroatoms selected from O, S and N, said 3–6 membered ring being optionally substituted with C 1-4 alkylene, oxo, ethylenedioxy or propylenedioxy, and being further optionally substituted with 1–4 groups selected from halo, C 1-4 alkyl, haloC 1-4 alkyl, C 1-3 acyl, C 1-3 acyloxy, C 1-3 alkoxy, C 1-6 alkylOC(O)—, C 2-4 alkenyl, C 2-4 alkynyl, C 1-3 alkoxyC 1-3 alkyl, C 1-3 alkoxyC 1-3 alkoxy, phenyl, CN, OH, D, NH 2 , NHR a and N(R a ) 2 wherein R a is as previously defined;
each R 1 represents H or is independently selected from the group consisting of: OH, halo, C 1-10 alkyl, C 1-6 alkoxy and C 6-10 aryl, said C 1-10 alkyl, C 6-10 aryl and the alkyl portion of C 1-6 alkoxy being optionally substituted with 1–3 halo, OH, OC 1-3 alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1–3 substituents independently selected from halo, OCH 3 , OCF 3 , CH 3 , CF 3 and phenyl, wherein said phenyl is optionally substituted with 1–3 halo groups,
or two R 1 groups taken together represent a fused C 5-6 alkyl or aryl ring, which may be optionally substituted with 1–2 OH or R a groups, wherein R a is as defined above;
R 2 and R 3 are taken together; and
represent (a) a C 3-8 alkanediyl forming a fused 5–10 membered non-aromatic ring optionally interrupted with 1–2 double bonds, and optionally containing 1–2 heteroatoms selected from O, S and N; or (b) a fused 6–10 membered aromatic monocyclic or bicyclic group, said alkanediyl and aromatic monocyclic or bicyclic group being optionally substituted with 1–6 halo atoms, and 1–4 of OH, C 1-3 alkyl, OC 1-3 alkyl, haloC 1-3 alkyl, haloC 1-3 alkoxy, and phenyl, said phenyl being optionally substituted with 1–4 groups independently selected from halo, C 1-3 alkyl, OC 1-3 alkyl , and said C 1-3 alkyl and the C 1-3 alkyl portion of OC 1-3 alkyl being optionally substituted with 1–3 halo groups.
2. The compound of claim 1 wherein A and B are taken separately and each represents a C 1-6 alkyl group, optionally substituted with 1–3 halo groups.
3. The compound of claim 1 wherein two R 1 groups represent H and one R 1 is selected from the group consisting of: OH, halo, C 1-10 alkyl, C 1-6 alkoxy and C 1-10 aryl, said C 1-10 alkyl, C 6-10 aryl and the alkyl portion of C 1-6 alkoxy being optionally substituted with 1–3 halo, OH, OC 1-3 alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1–3 substituents selected from: halo, OCH 3 , OCF 3 , CH 3 , CF 3 and phenyl, wherein said phenyl is optionally substituted with 1–3 halo groups.
4. The compound of claim 1 wherein one R 1 group represents H and two R 1 groups are selected from the group consisting of: OH, halo, C 1-10 alkyl and C 16 alkoxy, said C 1-10 alkyl and the alkyl portion of C 1-6 alkoxy being optionally substituted with 1–3 halo groups.
5. The compound of claim 4 wherein two R 1 groups represent halo or methyl.
6. The compound of claim 1 wherein R 2 and R 3 are taken together and represent: (a) a C 3-8 alkanediyl forming a fused 5–10 membered non-aromatic ring optionally interrupted with 1 double bond, and optionally interrupted by 1 heteroatom selected from O, S and N; or (b) a fused 6–10 membered aromatic monocyclic or bicyclic group, said alkanediyl and aromatic monocyclic or bicyclic group being optionally substituted with 1-3 halo atoms, and 1-2 of OH, C 1-3 alkyl, OC 1-3 alkyl, haloC 1-3 alkyl, haloC 1-3 alkoxy and phenyl, said phenyl being optionally substituted with 1–2 groups independently selected from halo, C 1-3 alkyl, OC 1-3 alkyl , and said C 1-3 alkyl and the C 1-3 alkyl portion of OC 1-3 alkyl being optionally substituted with 1–3 halo groups.
7. The compound of claim 1 selected from the table set forth below:
or a pharmaceutically acceptable salt or solvate thereof.
8. A pharmaceutical composition comprising a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.
9. A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient an effective amount of a compound in accordance with claim 1 .
10. A method of treating non-insulin dependent diabetes mellitus in a mammalian patient in need of such treatment comprising administering to the patient an anti-diabetic effective amount of a compound in accordance with claim 1 .
11. A method of treating obesity in a mammalian patient in need of such treatment compriseing administering to said patient a compound in accordance with claim 1 in an amount that is effective to treat obesity.
12. A method of treating Syndrome X in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with claim 1 in an amount that is effective to treat Syndrome X.
13. A method of treating a lipid disorder selected from the group conisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with claim 1 in an amount that is effective to treat said lipid disorder.
14. A method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with claim 1 in an amount effective to treat atherosclerosis.